Pediatric Large Cell/Anaplastic Medulloblastomas: Diagnostic Concordance and Multi‐Classifier DNA Methylation Profiling, Including the In‐House MAGIBU Framework
Neuropathology · 2026
DOI: 10.1111/neup.70080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropathology, 2026. Verfasst von Laura Giunti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Medulloblastoma, DNA Methylation, Cerebellar Neoplasms. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Ministero della Salute, CBTN, Per Elisa contro il Neuroblastoma - AVIS Comunale di Monsummano Terme.
Abstract (Originalsprache)
Large cell/anaplastic medulloblastoma is a high‐risk variant whose histopathological diagnosis can be challenging. We analyzed 12 pediatric cases enriched for LC/A morphology, with centralized review available for 11. In this deliberately selected, diagnostically challenging series, institutional and central LC/A versus non‐LC/A assessments were discordant in 36% (4 of 11), illustrating the difficulty of applying the LC/A designation rather than a general estimate of inter‐observer reproducibility. DNA methylation profiling was performed using four classifiers: Heidelberg CNS Tumor Methylation Classifier, Methylscape Analysis, EpiDiP, and the MAGIBU classifier, which applies a UMAP‐based distance approach. Tumor classification was largely concordant across platforms, identifying two WNT ‐activated medulloblastomas, eight non‐ WNT /non‐ SHH medulloblastomas, and one tumor reclassified as an embryonal tumor with multilayered rosettes. One misclassification occurred with EpiDiP, where an SHH ‐activated medulloblastoma aligned with the normal cerebellar cortex reference profile. Copy number analysis revealed MYC amplification in two non‐ WNT /non‐ SHH tumors, chromosome 6 loss in both WNT ‐activated cases, and isochromosome 17q in one MYC ‐amplified non‐ WNT /non‐ SHH tumor. Adjunctive molecular data for a subset of cases were obtained from PedcBioPortal. The reclassified tumor lacked canonical molecular alterations but harbored additional CTNNB1 and TP53 variants whose contribution to its pathogenesis remains uncertain. One WNT ‐activated medulloblastoma also carried a CTNNB1 variant. The MAGIBU classifier correctly identified the ETMR case, classified all remaining tumors as medulloblastomas, and showed concordant subgroup assignment with the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis, including the SHH ‐activated case misclassified by EpiDiP. On external validation across four independent medulloblastoma cohorts ( n = 1063), MAGIBU achieved 98.5% family‐level recall and 96.4% subclass‐level recall. In conclusion, our findings indicate that, in these diagnostically challenging, LC/A‐enriched cases, morphology‐based diagnostic assessment can be inconsistent. DNA methylation profiling serves to refine tumor reclassification and ensure accurate risk stratification. Interpreting each tumor across complementary classifiers provides a triangulation that enhances diagnostic robustness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuro-Oncology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- UOR4 Cellular and Morphofunctional Neurobiology, Meyer Children's Hospital IRCCS, Florence, Italy.
- Pathology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Neuro-Surgery Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Medical Genetics, Meyer Children's Hospital IRCCS, Florence, Italy.
- Department of Information Engineering, University of Florence, Florence, Italy.
ORCID-Profile: Laura Giunti, Gianluca Mattei, Chiara Caporalini, Mirko Scagnet, Federico Mussa, Rina Agushi, Debora Vergani, Anna Maria Buccoliero
Förderung
- Ministero della Salute
- CBTN
- Per Elisa contro il Neuroblastoma - AVIS Comunale di Monsummano Terme
Zitieren
APA
Giunti, L., Mattei, G., Caporalini, C., Scagnet, M., Mussa, F., Agushi, R., Guidi, M., Vergani, D., Balasco, D., Civale, V. Y., Carnevali, C., Genitori, L., Magi, A., Sardi, I., & Buccoliero, A. M. (2026). Pediatric Large Cell/Anaplastic Medulloblastomas: Diagnostic Concordance and Multi‐Classifier DNA Methylation Profiling, Including the In‐House MAGIBU Framework. Neuropathology. https://doi.org/10.1111/neup.70080
Vancouver
Giunti L, Mattei G, Caporalini C, Scagnet M, Mussa F, Agushi R, et al. Pediatric Large Cell/Anaplastic Medulloblastomas: Diagnostic Concordance and Multi‐Classifier DNA Methylation Profiling, Including the In‐House MAGIBU Framework. Neuropathology. 2026. doi:10.1111/neup.70080
BibTeX
@article{Giunti2026,
author = {Giunti, Laura and Mattei, Gianluca and Caporalini, Chiara and Scagnet, Mirko and Mussa, Federico and Agushi, Rina and Guidi, Milena and Vergani, Debora and Balasco, Daniela and Civale, Vincenzo Yuto and Carnevali, Chiara and Genitori, Lorenzo and Magi, Alberto and Sardi, Iacopo and Buccoliero, Anna Maria},
title = {Pediatric Large Cell/Anaplastic Medulloblastomas: Diagnostic Concordance and Multi‐Classifier DNA Methylation Profiling, Including the In‐House MAGIBU Framework},
journal = {Neuropathology},
year = {2026},
doi = {10.1111/neup.70080}
}
EUVIMED